LH vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Labcorp (LH) presents a mixed profile with a stable Piotroski F-Score of 4/9 and a current price ($259.57) positioned between its defensive Graham Number ($157.1) and growth-based intrinsic value ($308.57). While the company demonstrates strong earnings growth (15.7% YoY) and a highly attractive forward P/E of 13.46, these fundamentals are countered by a bearish technical trend and significant insider selling. The long-term earnings track record is exceptional, but the lack of immediate momentum and mediocre health score suggest a neutral short-term outlook.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LH vs LLY: Head-to-Head Comparison
This page compares Labcorp Holdings Inc. (LH) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.